G. REMOND

635 total citations
17 papers, 494 citations indexed

About

G. REMOND is a scholar working on Molecular Biology, Organic Chemistry and Cellular and Molecular Neuroscience. According to data from OpenAlex, G. REMOND has authored 17 papers receiving a total of 494 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 6 papers in Organic Chemistry and 4 papers in Cellular and Molecular Neuroscience. Recurrent topics in G. REMOND's work include Neuropeptides and Animal Physiology (4 papers), Chemical Synthesis and Analysis (3 papers) and Synthesis and biological activity (2 papers). G. REMOND is often cited by papers focused on Neuropeptides and Animal Physiology (4 papers), Chemical Synthesis and Analysis (3 papers) and Synthesis and biological activity (2 papers). G. REMOND collaborates with scholars based in France and Canada. G. REMOND's co-authors include Michel Laubie, Henri Schmitt, M Vincent, Bernard Portevin, Michel Vincent, Guillaume De Nanteuil, Bernard Serkiz, Yolande Hervé, J. Lépagnol and Jean A. Boutin and has published in prestigious journals such as Journal of Medicinal Chemistry, European Journal of Biochemistry and Biochemical Pharmacology.

In The Last Decade

G. REMOND

15 papers receiving 464 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
G. REMOND France 9 294 200 122 76 53 17 494
Otto W. Woltersdorf United States 12 400 1.4× 147 0.7× 161 1.3× 35 0.5× 65 1.2× 20 663
Sham S. Nikam United States 18 339 1.2× 207 1.0× 310 2.5× 33 0.4× 75 1.4× 28 696
A. M. Triggle United States 6 331 1.1× 150 0.8× 237 1.9× 19 0.3× 49 0.9× 11 566
James S. Frazee United States 12 281 1.0× 140 0.7× 213 1.7× 30 0.4× 147 2.8× 22 626
D. Andrew Stevenson United States 15 214 0.7× 154 0.8× 80 0.7× 131 1.7× 35 0.7× 20 761
Peter W. R. Caulkett United Kingdom 10 371 1.3× 88 0.4× 231 1.9× 30 0.4× 65 1.2× 13 689
John A. Butera United States 19 484 1.6× 175 0.9× 312 2.6× 43 0.6× 74 1.4× 38 945
Sandra L. Cockerham United States 10 188 0.6× 210 1.1× 68 0.6× 31 0.4× 83 1.6× 25 521
Jung‐Hui Sun United States 7 199 0.7× 149 0.7× 263 2.2× 30 0.4× 42 0.8× 12 664
Grant Wishart United Kingdom 13 397 1.4× 103 0.5× 218 1.8× 68 0.9× 29 0.5× 29 633

Countries citing papers authored by G. REMOND

Since Specialization
Citations

This map shows the geographic impact of G. REMOND's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. REMOND with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. REMOND more than expected).

Fields of papers citing papers by G. REMOND

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. REMOND. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. REMOND. The network helps show where G. REMOND may publish in the future.

Co-authorship network of co-authors of G. REMOND

This figure shows the co-authorship network connecting the top 25 collaborators of G. REMOND. A scholar is included among the top collaborators of G. REMOND based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. REMOND. G. REMOND is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
REMOND, G., Bernard Portevin, J Bonnet, et al.. (1997). Pharmacological profile of a novel series of NK1 antagonists. In vitro and in vivo potency of benzimidazolone derivatives. European Journal of Medicinal Chemistry. 32(11). 843–868. 17 indexed citations
2.
3.
Portevin, Bernard, G. REMOND, Yolande Hervé, et al.. (1996). New Prolyl Endopeptidase Inhibitors:  In Vitro and in Vivo Activities of Azabicyclo[2.2.2]octane, Azabicyclo[2.2.1]heptane, and Perhydroindole Derivatives. Journal of Medicinal Chemistry. 39(12). 2379–2391. 87 indexed citations
4.
Kraus‐Berthier, Laurence, et al.. (1993). In vivo immunopharmacological properties of tuftsin and four analogs. Immunopharmacology. 25(3). 261–267. 3 indexed citations
5.
Boutin, Jean A., et al.. (1993). Myristoyl‐CoA: protein N‐myristoyltransferase activity in cancer cells. European Journal of Biochemistry. 214(3). 853–867. 44 indexed citations
6.
Marchand, Bernard, et al.. (1992). Synthesis and ACE inhibitory activity of the stereoisomers of perindopril (S 9490) and perindoprilate (S 9780).. PubMed. 9(1). 11–28. 25 indexed citations
7.
Vincent, Michel, Claudine Pascard, Michèle Césario, et al.. (1992). Synthesis and conformational studies of Zabicipril (S 9650-3), a potent inhibitor of angiotensin converting enzyme. Tetrahedron Letters. 33(48). 7369–7372. 14 indexed citations
8.
Kraus‐Berthier, Laurence, et al.. (1991). Approaches to some biochemical mechanisms of action of tuftsin and analogues. Biochemical Pharmacology. 41(10). 1411–1418. 7 indexed citations
9.
10.
Boutin, Jean A., et al.. (1991). N‐Myristoyl‐transferase activity in cancer cells. European Journal of Biochemistry. 201(1). 257–263. 9 indexed citations
11.
12.
REMOND, G., et al.. (1982). Stereoselective synthesis of a new perhydroindole derivative of chiral iminodiacid, a potent inhibitor of angiotensin converting enzyme. Tetrahedron Letters. 23(16). 1677–1680. 71 indexed citations
13.
Laubie, Michel, Henri Schmitt, M Vincent, & G. REMOND. (1977). Central cardiovascular effects of morphinomimetic peptides in dogs. European Journal of Pharmacology. 46(1). 67–71. 167 indexed citations
14.
Vincent, Michel, et al.. (1977). Condensation du méthane disulfochlorure avec quelques diamines 1,2 et 1, 3 études des hétérocycles obtenus. Journal of Heterocyclic Chemistry. 14(3). 493–495.
15.
REMOND, G., et al.. (1973). Di-.alpha.-[4-Isobutyl(cyclohexen-1-yl)]alkanoic acids and derivatives as fibrinolytic and thrombolytic compounds. Journal of Medicinal Chemistry. 16(6). 710–712.
16.
Vincent, Michel, et al.. (1972). d1-.alpha.-(4-Cycloalkyl-1-cyclohexenyl)alkanoic acids and derivatives as antiinflammatory and antiarthritic compounds. Journal of Medicinal Chemistry. 15(1). 75–79. 2 indexed citations
17.
Vincent, Michel, et al.. (1971). 2-(Alkenylamino)benzamides and related 1-(alkenyl)-4(1H)-quinazolinones as analgetics and antiinflammatories. Journal of Medicinal Chemistry. 14(8). 714–717. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Otto W. Woltersdorf Breakdown of academic impact, for papers by Sham S. Nikam Breakdown of academic impact, for papers by A. M. Triggle Breakdown of academic impact, for papers by James S. Frazee Breakdown of academic impact, for papers by D. Andrew Stevenson Breakdown of academic impact, for papers by Peter W. R. Caulkett Breakdown of academic impact, for papers by John A. Butera Breakdown of academic impact, for papers by Sandra L. Cockerham Breakdown of academic impact, for papers by Jung‐Hui Sun Breakdown of academic impact, for papers by Grant Wishart
Rankless by CCL
2026